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water contamination from a single source can result in wide-
spread cases.
Table 1. Outbreak Investigation
Process/
practice
reviews
Changes
DescriptionY N
Infection
Control
Surveillance
 Performed point prevalence
surveys (rectal cultures) and/or
roommate contact tracing after
each MBL-Psa cluster/case;
established weekly rectal
surveillance (week 24 of
outbreak)
Hand hygiene  Reviewed hand hygiene practices;
increased usage of alcohol hand
rub; recommended against
artificial nails/nail extenders
Central line
care
 Relocated CVC flush processes
away from handwashing sink
Housekeeping  Enhanced unit environmental
cleaning; intermittently attempted
sink drain decontamination (1:
1000 ppm sodium hypochlorite);
discontinued use of contaminated
spray cleaner/deodorizer
Equipment
cleaning
 Reviewed and reorganized
processes
Education  Reviewed Standard Practice and
isolation precautions with all
staff; provided ongoing
education/outbreak feedback to
stakeholders
Patient Care  Restricted routine use of
Carbapenems for febrile
neutropenia; discontinued use of
Ciprofloxacin prophylaxis;
discontinued off-service
admissions; initiated private room
accomodation for all
BMT/hematology/ febrile
neutropenic patients; reinforced
sterile water for nebulizers;
discontinued ambient air
nebulizers for patients with
mucositis; continued contact
isolation for presumptive/
confirmed cases
Environmental
Culturing and
Maintenance
 Performed repeated environmental
and water cultures; removed
faucet aerators and sink stoppers;
replaced medication room/staff
washroom sinks, tub, all sink
grout, and one cold water shut-off
valve
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TEMPORAL THERMOMETER USE FOR MONITORING BONE MARROW
TRANSPLANTATION PATIENTS: COMPARISON WITH ORAL THERMOM-
ETER
Akins, P.A., Mobley, S.A., Scott, D., Rybicki, L. Cleveland Clinic
Foundation, Cleveland, OH.
Monitoring Bone Marrow Transplant (BMT) patients for fever is
essential assessment data for early recognition of infection. The
current method of monitoring is oral thermometry (OT). How-
ever, a signiﬁcant number of BMT patients experience oral mu-
cositis, making fever monitoring uncomfortable. Mucositis pain
may prevent patients from being able to correctly place the ther-
mometer, affecting the accuracy of the readings. The temporal
thermometer (TT) is an alternative method of assessment. The
purpose of this project is to explore the differences between TT
and OT monitoring in BMT patients and to assess patient comfort
associated with each method. BMT patients receive a myeloblative
chemotherapy regimen prior to transplant. Neutropenia occurs
within 2 to 3 weeks of therapy and is indicated when the neutrophil
count falls below 1000/mm3. Infection is the major cause of mor-
bidity and mortality among BMT patients. During the ﬁrst 3 to 4
weeks following transplantation, most patients will develop a fever.
In 30 to 40%, blood cultures show bacterial pathogens. A fever in
a neutropenic patient is deﬁned as a temperature 	38.0° C. Alter-
native methods of monitoring fever include pulmonary artery mea-
surement, rectal thermometers, tympanic thermometers, and tem-
poral thermometers. The use of pulmonary artery and rectal
thermometry are contraindicated, as any invasive procedure places
a pancytopenic patient at added risk for infection. The tympanic
thermometer readings can vary, depending on instrument place-
ment, making it unreliable for monitoring fever in BMT patients.
To date no studies have examined the use of TT for monitoring
fever in immunocompromised BMT patients. This is a prospective
exploratory study examining the differences between OT and TT
monitoring in BMT patients. Data will be collected 4 times a day
for 4 days from a convenience sample of BMT patients from M50.
Patients will receive usual routine fever monitoring using OT
method and simultaneously will have their temperature monitored
using the TT method. To standardize assessment of mucositis, the
Oral Mucosa Assessment Scale (OMAS) will be completed daily on
each patient. To assess discomfort, the RN or PCNA will ask the
patient to rate the level of comfort-discomfort related to place-
ment, using a 0 to 10 verbal rating scale. This proposal is still in a
data collection phase, and the ﬁndings may direct change for future
practice to beneﬁt future patients.
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NURSING CARE OF THE GRANULOCYTE DONOR FOR PEDIATRIC STEM
CELL TRANSPLANT PATIENTS
Stanton, T.J., Marconi, A.L., Allison, J., Kurtzberg, J. Duke Univer-
sity Hospital, Durham, NC.
Infection continues to be the leading cause of morbidity and
mortality in patients with severe and sustained neutropenia deﬁned
as an Absolute Neutrophil Count of 500/uL. Cesaro et. al (2003)
concludes that “granulocyte transfusion therapy is potentially use-
ful when the severity of the infection and the host’s immunodeﬁ-
ciency make any other antimicrobial therapy ineffectual.” The
Duke Pediatric Blood and Marrow Transplant program uses gran-
ulocyte transfusion therapy for persistently neutropenic patients
with severe infections and for patients who must undergo a second
bone marrow transplant. Donors are required to go through blood
donor questionnaires and blood testing to ensure the safety of both
the donor and the recipient per FDA donor regulations effective
5/25/2005. When possible, a CMV negative donor is selected.
Once a donor is selected (usually a relative of the patient) a double
lumen pheresis catheter is placed for the duration of the donation.
The donor is primed with G-CSF 10 mcg/kg twice weekly. Gran-
ulocytes are harvested by pheresis 14 to 16 hours post G-CSF
dosing, irradiated, divided into 3 doses, and administered IV to the
patient daily  3. With 2 pheresis per week, the recipient receives
granulocytes 6/7 days. Nurse coordinators and staff nurses on the
inpatient transplant unit collaborate to provide the majority of care
and education to the granulocyte donors in order to provide con-
sistency of care for families. The transplant patient’s nurse is
responsible for monitoring and maintaining the pheresis catheter
and for administering G-CSF by injection to the donor. The nurse
must also educate the donor about possible side effects of G-CSF
therapy and granulocyte donation as well as ways to prevent these
side effects. The purpose of this poster will be to (1) educate the
learner about the nurse’s responsibility in caring for the granulo-
cyte donor; (2) describe the standard operating procedure for daily
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care of the pheresis catheter; (3) describe the standards for dosing,
frequency, and administration of GCSF; (4) provide education
about the possible side effects of granulocyte donation and how
they may be prevented; (5) describe the potential emotional impli-
cations for the donor.
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NURSING CONSIDERATIONS FOR BMT PHOTOPHERESIS PATIENTS
Rhodes, B.A. M. D. Anderson Cancer Center, Houton, TX.
Graft-versus-Host Disease (GVHD) is a common complication and
limitation of allogeneic hematopoietic stem cell transplantation.
GVHD has a profound impact on the patient’s quality of life and long
term survival rate. Conventional therapy for GVHD is often associ-
ated with signiﬁcant side effects and treatment related complications.
Research is ongoing to ﬁnd better ways to treat GVHD. One treat-
ment modality that appears promising is photopheresis or extracor-
poreal photochemotherapy. Recent studies have shown photopheresis
to have efﬁcacy for the treatment of GVHD of skin, liver, lung, oral
mucosa, and eyes. Photopheresis is an immunomodulatory therapy
that utilizes the leukapheresis of white blood cells, methoxsalen, and
ultraviolet light. Photopheresis was approved by the Food and Drug
Administration in 1988 for the treatment of Cutaneous T-Cell Lym-
phoma. Many photopheresis procedures have been successfully per-
formed on this patient population without complications. The BMT
patient with GVHD is a complex patient with issues such as anemia,
thrombocytopenia, and immunosuppression. These issues can in-
crease the complexity and complications of any procedure. Our center
currently performs approximately 150 photopheresis treatments per
month. Nursing guidelines have been established to minimize and
prevent complications to provide a safe and effective treatment for this
complex patient population. Patient education, order sets, progress
notes, and procedure worksheets were also developed to streamline
the procedure. Photopheresis appears to be an exciting and promising
therapy for the treatment of some forms of GVHD. Nursing guide-
lines and interventions can make a difference to ensure a successful
photopheresis treatment.
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ACUTE HYPERTENSIVE CRISIS DURING INFUSION OF HEMATOPOIETIC
PROGENITOR CELL FROM MATCHED UNRELATED DONORS: IDENTIFI-
CATION OF PREDICTIVE FACTORS AND OPTIMAL TREATMENT
Blackburn, R.K., Giralt, S.A., Saliba, R.M., Rondon, G., Fenwick, J.N.
UTMDACC, Houston, TX.
Background: Acute hypertensive crisis during autologous hemato-
poietic progenitor cell (HPC) infusions using DMSO is widely re-
ported, but the literature is silent regarding this event during infusions
of HPC from matched unrelated donors (MUD). MUD-HPC infu-
sions are often given by evening nursing staff when there is less clinical
support in the hospital, and treatment varies with physician prefer-
ence. Identiﬁcation of predictive factors and of optimal treatment may
lead to improved outcomes. Purpose: To identify predictive factors
for the development of acute hypertensive crisis, and to develop best
treatment pathways. Methods: A retrospective review of 97 adult
patients receiving MUD HPC infusions from October 2003 to Sep-
tember 2004 was done. Demographic, clinical, and laboratory factors
were evaluated for the occurrence of hypertensive crisis using regres-
sion analysis. This analysis was limited to patients receiving HPC-
marrow infusions because only 2/20 cases occurred among patients
receiving PBSC. Hypertensive crisis was deﬁned as SBP 	 160,
DBP 	 100, or a symptomatic increase in BP of 20 mm HG 	
baseline.Results:On univariate analysis, volume infused (adjusted for
weight), elevated creatinine (	1.0 mg/dl), and BUN levels above the
median (	15 mg/dl) were signiﬁcant predictors. Because of high
correlation between BUN and creatinine, only BUN was considered
in multivariate analysis (higher precision associated with the estimate).
Patients receiving high volume infusions with an elevated BUN were
at the greatest risk (62%), followed by patients receiving high volume
infusions and low BUN (28%), and then by patients receiving low
volume and high BUN (17%). There were no cases of hypertension
among the 18 patients who received low volumes and had a low BUN.
Medical treatment during hypertensive episodes varied but best re-
sponses were seen with combined use of IV antihypertensive agents
and diuretics. Recommendations: These ﬁndings suggest that vol-
ume reduction of HPC-M may decrease the incidence of acute hy-
pertensive crisis during MUD infusions (Table 1).
Table 1. Patient Characteristics
Continuous
variables Number
Yes HTN
Crisis
No HTN
Crisis
p
value OR
95%
CI
Age 49 (25-67) 49 (23-71) 0.9
Prior Chemo 2 (0-11) 2.5 (0-9) 0.7
Volume Infused/
Weight 20 (4-29) 6 (0.6-25) 0.001
<4 20 1 (5%)
4-9 16 2(12%)
10-20 18 6 (33%)
>20 16 9 (56%)
<9 36 3 (8%)
>9 34 15 (44%) 0.002 8.7 2.2-33.9
Weight at infusion 79 (59-119) 88 (56-158) 0.2
WBC 0.85 (0.1-5.3) 0.7 (0-15) 0.7
HGB 10.4 (7.9-14) 9.4 (7.4-8.6) 0.26
Hct 30 (22-44) 26 (20-38) 0.1
Plt 59 (4-336) 51 (1-222) 0.9
Acg 0.23 (0-5) 0.68 (0-6) 0.14
Na 139 (136-145) 139 (132-144) 0.3
K 4.1 (2.9-6.3) 3.9 (3.2-5.4) 0.7
Cl 105 (101-115) 107 (99-113) 0.9
CO2 27 (20-32) 27 (21-56) 0.7
Alb 3 (2.2-4.1) 3.1 (2.3-8.8) 0.5
Creatinine 0.95(0.5-2.8) 0.8 (0.5-2.1) 0.03
<1 57 11 (19%)
>1 13 7 (54%) 0.02 4.9 1.4-17
BUN 19 (11-67) 15 (6-71) 0.03
<12 19 2 (11%)
13-15 17 3 (18%)
16-21 19 8 (42%)
>21 15 5 (33%)
<15 36 5 (14%)
>15 34 13 (13%)
Tacro levels 11.5 (3.7-30) 10 (3.1-22.7) 0.3
Categorical
variables
Male 39 10 29
Female 31 8 23 0.9 ref. 1 0.3-2-9
Prior Allo 62 17
No Prior Allo 5 0 5
Prior Auto 11 4 7 0.4 ref 1.9 0.5-7.5
No Prior Auto 56 13 43
Hx of HTN 12 3 9
No Hx HTN 58 15 43 0.9 ref 0.9 0.2-4.0
Hx Diabetes 9 3 6 0.6 ref 1.5 0.3-6.9
No Hx Diabetes 61 15 46
Hx Cardiac Dis 14 5 9 0.3 1.8 0.5-6.5
No Hx Cardiac
Disease 56 13 43
Hx surgery 32 7 25 0.5 ref 0.7 0.2-2.0
No Hx Surgery 38 11 27
Hx Renal disease 4 2 2 0.3 3.1 0.4-24
No Hx Renal dis 66 16 50
Diuretics Used 5 1 4 0.8 0.7 0.1-6.8
No diuretics used 65 17 48
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THE RISK OF GRAFT-VERSUS-HOST DISEASE (GVHD) VARIES WITH
DIFFERENT MYELOABLATIVE REGIMENS: IV BUSULFAN/FLUDARABINE
(IV BuFlu) VERSUS IV BUSULFAN/CYCLOPHOSPHAMIDE (IV BuCy)
VERSUS FLUDARABINE/MELPHALAN (FM)
Mickler, K.L., Saliba, R., Ghosh, S., de Lima, M., Giralt, S., Kim, S.,
Andersson, B., Khouri, I., Champlin, R.E., Couriel, D. The University
of Texas M.D. Anderson Cancer Center, Houston, TX.
Objective: To compare the incidence of GVHD and non-re-
lapse mortality (NRM) among different myeloablative preparative
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